摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-羟基-5-甲基-N-苯基 - 2-1H吡啶酮 | 887406-53-3

中文名称
3-羟基-5-甲基-N-苯基 - 2-1H吡啶酮
中文别名
——
英文名称
3-Hydroxy-5-methyl-N-phenyl-2-1H-pyridone
英文别名
3-hydroxy-5-methyl-1-phenylpyridin-2-one
3-羟基-5-甲基-N-苯基 - 2-1H吡啶酮化学式
CAS
887406-53-3
化学式
C12H11NO2
mdl
MFCD07369448
分子量
201.22
InChiKey
YQWKULMIIVZAOS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    108-109°C
  • 沸点:
    365.1±42.0 °C(Predicted)
  • 密度:
    1.275±0.06 g/cm3(Predicted)
  • 溶解度:
    乙腈(少量溶解)。氯仿(少量溶解)、DMSO(少量溶解)、甲醇(少量溶解)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.083
  • 拓扑面积:
    40.5
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds
    申请人:Olgin Jeff
    公开号:US20100029578A1
    公开(公告)日:2010-02-04
    The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF).
    本发明涉及通常用于治疗或预防房颤(AF)的化合物和方法。
  • METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS
    申请人:Olgin Jeff
    公开号:US20120046321A1
    公开(公告)日:2012-02-23
    The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF).
    本发明涉及一般与化合物和方法有关,用于治疗或预防心房颤动(AF)。
  • METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM
    申请人:Blatt Lawrence M.
    公开号:US20120258924A1
    公开(公告)日:2012-10-11
    Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
    本发明涉及使用活性化合物调节应激激活蛋白激酶(SAPK)系统的方法,其中该活性化合物对至少一种p38 MAPK抑制的效力较低;并且该接触是在该化合物对至少一种p38 MAPK的抑制浓度低百分比的SAPK调节浓度下进行的。本发明还涉及吡非尼酮的衍生物,这些衍生物可以调节应激激活蛋白激酶(SAPK)系统。
  • Method of modulating stress-activated protein kinase system
    申请人:Intermune, Inc.
    公开号:EP2426134A2
    公开(公告)日:2012-03-07
    It has now been discovered that a high therapeutic effect in treating various disorders associated with enhanced activity of kinase p38 may be achieved by using a potent p38? kinase inhibitor compound which also has inhibitory activity against p38?. Furthermore, reducing the activities of both kinase p38? and kinase p38? without reducing the activity of a kinase p38? to such an extent that undesired side effects are observed upon administration to a subject having a disorder associated with enhanced activity of kinase p38 has been discovered to be achievable by modifying inhibitors of p38? such that the modification engenders inhibitory activity against p38?. Described are compounds with activity against p38? and p38?.; Disclosed are methods of using described compounds and compositions to modulate a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits inhibition of the p38? and p38? MAPKs. Also disclosed are methods for identifying compounds which inhibit p38? and p38? MAPKs and which can modulate a stress activated protein kinase (SAPK) system.
    现已发现,通过使用一种对 p38?激酶也具有抑制活性的强效 p38?激酶抑制剂化合物,可以在治疗与 p38?激酶活性增强有关的各种疾病方面取得很高的治疗效果。此外,已经发现通过修饰 p38?的抑制剂,使其对 p38?具有抑制活性,可以降低激酶 p38?和激酶 p38?的活性,而不会降低激酶 p38?的活性,以至于在对患有与激酶 p38?活性增强相关的疾病的受试者用药时观察到不期望的副作用。和p38?的活性的化合物;公开了使用所述化合物和组合物以活性化合物调节应激活化蛋白激酶(SAPK)系统的方法,其中活性化合物表现出抑制p38?MAPKs 的抑制作用。还公开了鉴定抑制 p38?和 p38?MAPKs 并能调节应激活化蛋白激酶(SAPK)系统的化合物的方法。
  • Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
    申请人:Intermune, Inc.
    公开号:EP2591784A1
    公开(公告)日:2013-05-15
    Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
    公开了用活性化合物调节应激活化蛋白激酶(SAPK)系统的方法,其中活性化合物对抑制至少一种p38 MAPK表现出较低的效力;并且接触是在SAPK调节浓度下进行的,该浓度是化合物抑制至少一种p38 MAPK的低百分比抑制浓度。还公开了吡非尼酮的衍生物。这些衍生物可以调节应激活化蛋白激酶(SAPK)系统。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-